<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969942</url>
  </required_header>
  <id_info>
    <org_study_id>13.0176</org_study_id>
    <nct_id>NCT01969942</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma</brief_title>
  <acronym>ASCT</acronym>
  <official_title>A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the toxicity of using allogeneic stem cell
      transplantation for treatment of subjects with relapsed or refractory Ewing Sarcoma (ES).
      Donors will consist of either Human Leukocyte Antigen identical (HLA)or 9/10 (A, B, C, DR, DQ
      [A, B, C, are Class I markers for HLA and DR and DQ are Class II markers for Matching for
      Transplant for Donors to match with recipient]) matched related or unrelated donors.
      Specifically, we will examine:

        -  The toxicity of allogeneic stem cell transplant (SCT) in this patient population, as
           related to incidence of grade 3-4 acute Graft Verse Host Disease (GVHD).

        -  The incidence of transplant related mortality at 100 days.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subjects meeting study inclusion were enrolled.
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Grade 3-4 GVHD</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ewing Sarcoma</condition>
  <arm_group>
    <arm_group_label>allogeneic stem cell transplantation Plan A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive the vaccine, Busulfan and Melphalan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>allogeneic stem cell transplantation Plan B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If subject have already received a stem cell transplant using Busulfan and Melphalan, they will receive Clysophosohamide and Fludarabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic stem cell transplantation</intervention_name>
    <arm_group_label>allogeneic stem cell transplantation Plan A</arm_group_label>
    <arm_group_label>allogeneic stem cell transplantation Plan B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clyclophosphamide</intervention_name>
    <arm_group_label>allogeneic stem cell transplantation Plan B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabina</intervention_name>
    <arm_group_label>allogeneic stem cell transplantation Plan B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <arm_group_label>allogeneic stem cell transplantation Plan A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>allogeneic stem cell transplantation Plan A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 0-30 years with relapsed or therapy refractory Ewings sarcoma, excluding
             patients with brain metastases. Patients who have received a prior autologous stem
             cell transplant are eligible.

          -  Related and unrelated marrow and peripheral blood stem donors must be 9/10 or 10/10
             (HLA A, B, C, DR, DQ) matched with the recipient.

        Exclusion Criteria:

          -  Organ dysfunction: Patients who have the following levels of organ system dysfunction
             are not eligible:

               -  Cardiac: Ejection Fraction less than 50 percent

               -  Renal: Est. Creatinine Clearance less than 50

               -  Hepatic: Bilirubin greater than 3.0

               -  Pulmonary: Diffusing Capacity for Carbon Monoxide (DLCO) less than 70 percent, or
                  for patient who cannot cooperate with pulmonary function testing, O2 saturation
                  less than 95 percent on room air.

          -  Performance status: Lansky performance less than 70; Eastern Cooperative Oncology
             Group (ECOG) status greater than or equal to 2

          -  Patients with an isolated recurrence of their tumor (in the site of primary tumor)
             greater than 1 year after completing therapy are excluded as these patients could be
             cured with local therapy alone.

               -  As part of the standard of care for pre-transplant evaluation subjects will be
                  tested for exposure to viral agents such as hepatitis B, C, HTLV-1/2 and HIV.
                  Subjects testing positive for HI may be rejected as candidates for
                  transplantation, based on the clinical judgement of the stem cell transplant
                  physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Lucas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://louisville.edu/medschool/pediatrics/clinical/sections-divisions/hem-onc</url>
    <description>University of Louisville Peds--Heme/Onc</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ewings sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

